Rhinocerebral Mucormycosis as a Sequelae of COVID-19 Treatment: A Case Report & Literature Review.
| Autor: | Deek AJ; Resident physician, Department of Oral & Maxillofacial Surgery, University of Tennessee Medical Center in Knoxville, Knoxville, TN. Electronic address: ADeek@utmck.edu., Boukovalas S; Assistant Professor, Department of Plastic & Reconstructive Surgery, University of Tennessee Medical Center in Knoxville, Knoxville, TN., Rathfoot CJ; Attending Physician, Department of Otolaryngology, Knoxville, TN., Gotcher JE; Program director, Department of Oral & Maxillofacial Surgery, University of Tennessee Medical Center in Knoxville, Knoxville, TN. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons [J Oral Maxillofac Surg] 2022 Feb; Vol. 80 (2), pp. 333-340. Date of Electronic Publication: 2021 Sep 20. |
| DOI: | 10.1016/j.joms.2021.09.009 |
| Abstrakt: | A large volume of reports detailing a marked increase in Mucormycosis infections in India has filtered its way into world news articles. These patients frequently have 2 risk factors: recent treatment of COVID-19 with high dose steroids, and uncontrolled diabetes. Recently, at the University of Tennessee Medical Center in Knoxville, we successfully treated an uncontrolled diabetic patient with rhinocerebral Mucormycosis as a sequela of his COVID-19 treatment. (Published by Elsevier Inc.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|